U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung CancerPRNewsWire • 12/18/25
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-TermZacks Investment Research • 12/09/25
The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.The Motley Fool • 12/06/25
Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report?Zacks Investment Research • 12/03/25
Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference TranscriptSeeking Alpha • 12/02/25
Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug DeliveryPRNewsWire • 11/18/25
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of PetosemtamabPRNewsWire • 11/17/25
FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple MyelomaPRNewsWire • 11/07/25
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032PRNewsWire • 11/07/25
Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a LookThe Motley Fool • 11/05/25
Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032PRNewsWire • 11/05/25
Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue EstimatesZacks Investment Research • 11/04/25
Halozyme Therapeutics (HALO) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 11/04/25
HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTSPRNewsWire • 11/03/25